- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03445663
Study Evaluating AMG 424 in Subjects With Multiple Myeloma
A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects With Multiple Myeloma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Part 1 of the study is dose evaluating and aimed at assessing the safety and tolerability of AMG 424 while determining the maximum tolerated dose (MTD) and/or biologically active dose in subjects with relapsed/ refractory multiple myeloma.
Part 2 of the study will further evaluate safety and tolerability of the AMG 424 MTD dose determined in Part 1, in groups of subjects with relapsed/ refractory multiple myeloma that include those with high or low cytogenetic risk.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Research Site
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- Research Site
-
-
-
-
California
-
San Francisco, California, United States, 94143
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Research Site
-
Winston-Salem, North Carolina, United States, 27157
- Research Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Research Site
-
-
Washington
-
Seattle, Washington, United States, 98104
- Research Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Multiple myeloma meeting the following criteria:
Pathologically-documented diagnosis of multiple myeloma that has relapsed after at least two prior lines of therapy that must include a proteasome inhibitor (PI), immunomodulatory drug (IMiD), and, where approved and available, anti-CD38 therapy in any order OR that is refractory to PI, IMiD, and anti-CD38 therapy.
◾Subjects who could not tolerate a PI, IMiDs, or a CD38-directed therapeutic antibody due to unacceptable toxicities are eligible to enroll in the study.
- Measurable disease as per IMWG response criteria
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
Exclusion Criteria:
- Known central nervous system involvement by multiple myeloma
Previously received allogeneic stem cell transplant and one or more of the following:
- received the transplant < 6 months prior to study Day 1
- received immunosuppressive therapy < 3 months prior to study Day 1
- any active acute graft versus host disease (GvHD), grade 2- 4, according to the Glucksberg criteria or active chronic GvHD requiring systemic treatment
- any systemic therapy against GvHD < 2 weeks prior to study Day 1
- Autologous stem cell transplantation less than 90 days prior to study day 1
- Multiple myeloma with IgM subtype
- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
- Evidence of primary or secondary plasma cell leukemia at the time of screening
- Waldenstrom's macroglobulinemia
- Amyloidosis
- Dexamethasone at cumulative doses of greater than 160 mg or equivalent <3 weeks prior to study Day 1 is not allowed. Use of topical or inhaled steroids is acceptable
- Anticancer treatment (chemotherapy, IMiD, PI, molecular targeted therapy) < 2 weeks prior to study Day 1
- Treatment with a therapeutic antibody targeting CD38 < 12 weeks prior to study Day 1
- Systemic radiation therapy or major surgery < 28 days prior to study Day 1 as well as focal radiotherapy < 14 days prior to study Day 1.
- Major surgery within 28 days prior to study Day 1
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AMG 424
Comparison of different dosages of AMG 424
|
Subjects will receive IV infusions of AMG 424
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject incidence of treatment emergent and treatment related adverse events as assessed by CTCAE version 4.0
Time Frame: 12 Months
|
Measure of Safety
|
12 Months
|
Subject incidence of dose limiting toxicities (DLTs)
Time Frame: 28 Days
|
Measure of Safety
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-tumor activity
Time Frame: 48 Months
|
Efficacy parameter measured by IMWG response criteria
|
48 Months
|
Duration of Response
Time Frame: 48 Months
|
Measure of Response
|
48 Months
|
Maximum concentration (Cmax) of AMG 424
Time Frame: 12 Weeks
|
Characterize the pharmacokinetic (PK) profile following treatment with AMG 424
|
12 Weeks
|
Minimum concentration (Cmin) of AMG 424
Time Frame: 12 Weeks
|
Characterize the pharmacokinetic (PK) profile following treatment with AMG 424
|
12 Weeks
|
Time of maximum concentration (Tmax) of AMG 424
Time Frame: 12 Weeks
|
Characterize the pharmacokinetic (PK) profile following treatment with AMG 424
|
12 Weeks
|
Area under the concentration-time curve (AUC) of AMG 424
Time Frame: 12 Weeks
|
Characterize the pharmacokinetic (PK) profile following treatment with AMG 424
|
12 Weeks
|
Time to progression
Time Frame: 48 Months
|
Measure of Response
|
48 Months
|
Progression-Free Survival
Time Frame: 48 Months
|
Measure of Response
|
48 Months
|
Overall Survival
Time Frame: 48 Months
|
Measure of Response
|
48 Months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- 20160445
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/ Refractory Multiple Myeloma
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
Carl Ola Landgren, MD, PhDBristol-Myers SquibbRecruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
AmgenCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaCanada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
-
Regeneron PharmaceuticalsActive, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; H. Lee Moffitt...CompletedMultiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Ionis Pharmaceuticals, Inc.Active, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
TakedaCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States, Canada
-
BeBetter Med IncCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's LymphomaChina
Clinical Trials on AMG 424
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Mitsubishi Tanabe Pharma CorporationVertex Pharmaceuticals IncorporatedCompleted
-
Mitsubishi Tanabe Pharma CorporationVertex Pharmaceuticals IncorporatedCompleted
-
AmgenCompletedAdvanced Solid TumorsBelgium, Canada, Australia, United States, Spain, Poland, France, Germany, Japan, United Kingdom
-
AmgenTerminatedCutaneous Lupus | LupusUnited States, Australia, Canada
-
AmgenTerminatedRelapsed/Refractory Acute Myeloid Leukemia (AML)United States, Korea, Republic of, Australia, Japan, Germany, Canada
-
Southwest Oncology GroupNational Cancer Institute (NCI)RecruitingLung Adenocarcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Squamous Non-Small Cell CarcinomaUnited States, Guam
-
AmgenCompleted
-
AmgenCompletedGlioblastoma or Malignant GliomaUnited States, Australia, Netherlands, Germany, Spain, France
-
Mitsubishi Tanabe Pharma CorporationVertex Pharmaceuticals IncorporatedCompleted